Nour Ershaid

Nour Ershaid

Auto-generated profile, based on publicly available information

Nour Ershaid

Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NENour Ershaid
Nour Ershaid
YSYoray Sharon
Yoray Sharon
HDHila Doron
Hila Doron
YRYael Raz
Yael Raz
OSOphir Shani
Ophir Shani
NENeta Erez
Neta Erez
Cancer-Associated Fibroblasts (CAFs) were shown to orchestrate tumour-promoting inflammation in multiple malignancies, including breast cancer. However, the molecular pathways that govern the inflammatory role of CAFs are poorly characterised. In this study we found that fibroblasts sense damage-associated molecular patterns (DAMPs), and in response activate the NLRP3 inflammasome pathway, resulting in instigation of pro-inflammatory signalling and secretion of IL-1β. This upregulation was evident in CAFs in mouse and in human breast carcinomas. Moreover, CAF-derived inflammasome signalling facilitated tumour growth and metastasis, which was attenuated when NLRP3 or IL-1β were specifically ablated. Functionally, CAF-derived inflammasome promoted tumour progression and metastasis by modulating the tumour microenvironment towards an immune suppressive milieu and by upregulating the expression of adhesion molecules on endothelial cells. Our findings elucidate a mechanism by which CAFs promote breast cancer progression and metastasis, by linking the physiological tissue damage response of fibroblasts with tumour-promoting inflammation.

2 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LMLea Monteran
Lea Monteran
NENour Ershaid
Nour Ershaid
HDHila Doron
Hila Doron
YZYael Zait
Yael Zait
YSYe’ela Scharff
Ye’ela Scharff
NENeta Erez
Neta Erez
Mortality from breast cancer is almost exclusively a result of tumor metastasis and resistance to therapy and therefore understanding the underlying mechanisms is an urgent challenge. Chemotherapy, routinely used to treat breast cancer, induces extensive tissue damage, eliciting an inflammatory response that may hinder efficacy and promote metastatic relapse. Here we show that systemic treatment with doxorubicin, but not cisplatin, following resection of a triple-negative breast tumor induces the expression of complement factors in lung fibroblasts and modulates an immunosuppressive metastatic niche that supports lung metastasis. Complement signaling derived from cancer-associated fibroblasts (CAFs) mediates the recruitment of myeloid-derived suppressor cells (MDSCs) to the metastatic niche, thus promoting T cell dysfunction. Pharmacological targeting of complement signaling in combination with chemotherapy alleviates immune dysregulation and attenuates lung metastasis. Our findings suggest that combining cytotoxic treatment with blockade of complement signaling in triple-negative breast cancer patients may attenuate the adverse effects of chemotherapy, thus offering a promising approach for clinical use.

1 March 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
LMLea Monteran
Lea Monteran
NENour Ershaid
Nour Ershaid
YSYe’ELa Scharff
Ye’ELa Scharff
YZYazeed Zoabi
Yazeed Zoabi
TSTamer Sanalla
Tamer Sanalla
NENeta Erez
Neta Erez
Bone is the most common site of breast cancer metastasis. Bone metastasis is incurable and is associated with severe morbidity. Utilizing an immunocompetent mouse model of spontaneous breast cancer bone metastasis, we profiled the immune transcriptome of bone metastatic lesions and peripheral bone marrow at distinct metastatic stages, revealing dynamic changes during the metastatic process. We show that cross-talk between granulocytes and T cells is central to shaping an immunosuppressive microenvironment. Specifically, we identified the PD-1 and TIGIT signaling axes and the proinflammatory cytokine IL1β as central players in the interactions between granulocytes and T cells. Targeting these pathways in vivo resulted in attenuated bone metastasis and improved survival, by reactivating antitumor immunity. Analysis of patient samples revealed that TIGIT and IL1β are prominent in human bone metastasis. Our findings suggest that cotargeting immunosuppressive granulocytes and dysfunctional T cells may be a promising novel therapeutic strategy to inhibit bone metastasis. Significance: Temporal transcriptome profiling of the immune microenvironment in breast cancer bone metastasis revealed key communication pathways between dysfunctional T cells and myeloid derived suppressor cells. Cotargeting of TIGIT and IL1β inhibited bone metastasis and improved survival. Validation in patient data implicated these targets as a novel promising approach to treat human bone metastasis.

7 August 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
NCNoam Cohen
Noam Cohen
DMDhanashree Mundhe
Dhanashree Mundhe
SDSarah K. Deasy
Sarah K. Deasy
OAOmer Adler
Omer Adler
NENour Ershaid
Nour Ershaid
NENeta Erez
Neta Erez
Metastatic cancer is largely incurable and is the main cause of cancer-related deaths. The metastatic microenvironment facilitates formation of metastases. Cancer-associated fibroblasts (CAF) are crucial players in generating a hospitable metastatic niche by mediating an inflammatory microenvironment. Fibroblasts also play a central role in modifying the architecture and stiffness of the extracellular matrix (ECM). Resolving the early changes in the metastatic niche could help identify approaches to inhibit metastatic progression. Here, we demonstrate in mouse models of spontaneous breast cancer pulmonary metastasis that fibrotic changes and rewiring of lung fibroblasts occurred at premetastatic stages, suggesting systemic influence by the primary tumor. Activin A (ActA), a TGFβ superfamily member, was secreted from breast tumors and its levels in the blood were highly elevated in tumor-bearing mice. ActA upregulated the expression of profibrotic factors in lung fibroblasts, leading to enhanced collagen deposition in the lung premetastatic niche. ActA signaling was functionally important for lung metastasis, as genetic targeting of ActA in breast cancer cells significantly attenuated lung metastasis and improved survival. Moreover, high levels of ActA in human patients with breast cancer were associated with lung metastatic relapse and poor survival. This study uncovers a novel mechanism by which breast cancer cells systemically rewire the stromal microenvironment in the metastatic niche to facilitate pulmonary metastasis. Significance: ActA mediates cross-talk between breast cancer cells and cancer-associated fibroblasts in the lung metastatic niche that enhances fibrosis and metastasis, implicating ActA as a potential therapeutic target to inhibit metastatic relapse.

17 June 2026
Verified
Other
Open access
LMLea Monteran
Lea Monteran
NENour Ershaid
Nour Ershaid
YSYe’ELa Scharff
Ye’ELa Scharff
YZYazeed Zoabi
Yazeed Zoabi
TSTamer Sanalla
Tamer Sanalla
NENeta Erez
Neta Erez
Bone is the most common site of breast cancer metastasis. Bone metastasis is incurable and is associated with severe morbidity. Utilizing an immunocompetent mouse model of spontaneous breast cancer bone metastasis, we profiled the immune transcriptome of bone metastatic lesions and peripheral bone marrow at distinct metastatic stages, revealing dynamic changes during the metastatic process. We show that cross-talk between granulocytes and T cells is central to shaping an immunosuppressive microenvironment. Specifically, we identified the PD-1 and TIGIT signaling axes and the proinflammatory cytokine IL1β as central players in the interactions between granulocytes and T cells. Targeting these pathways in vivo resulted in attenuated bone metastasis and improved survival, by reactivating antitumor immunity. Analysis of patient samples revealed that TIGIT and IL1β are prominent in human bone metastasis. Our findings suggest that cotargeting immunosuppressive granulocytes and dysfunctional T cells may be a promising novel therapeutic strategy to inhibit bone metastasis.Significance:Temporal transcriptome profiling of the immune microenvironment in breast cancer bone metastasis revealed key communication pathways between dysfunctional T cells and myeloid derived suppressor cells. Cotargeting of TIGIT and IL1β inhibited bone metastasis and improved survival. Validation in patient data implicated these targets as a novel promising approach to treat human bone metastasis.

1 July 2024
Verified
Other
Open access
PDF file
LMLea Monteran
Lea Monteran
NENour Ershaid
Nour Ershaid
YSYe’ela Scharff
Ye’ela Scharff
YZYazeed Zoabi
Yazeed Zoabi
TSTamer Sanalla
Tamer Sanalla
NENeta Erez
Neta Erez
Supplementary Figure 1: Bone metastasis immunosuppressive microenvironment. Supplementary Figure 2: Gating strategy for RNA sequencing. Supplementary Figure 3: Differentially expressed genes during breast cancer bone metastasis progression. Supplementary Figure 4: Metastasis-infiltrating T cells are profoundly altered by metastatic progression. Supplementary Figure 5: Immune Checkpoint Receptors (ICRs) are expressed by metastasis-infiltrating T cells. Supplementary Figure 6: Targeting TIGIT results in activation of T cell mediated anti-tumor immunity. Supplementary Figure 7: (a) Spinal Cord Compression occurrence in treated mice. P-values were calculated using two-sided Chi square test. Supplementary Figure 8: TIGIT is highly expressed in human bone metastasis. Supplementary Table 1: Patient cohort data. Supplementary Table 2: Primers sequences.